Release Date: 28-May-2025
The US orphan drugs market is a compelling success story of pharmaceutical innovation, turning long-ignored therapeutic areas into a lucrative industry worth around US$ 100 billion as of 2024. The niche market segment has witnessed phenomenal growth, with KuicK Research’s estimates suggesting it may become a market opportunity of US$ 200 billion by 2030. The economic sustainability of developing treatments for rare diseases is due to a mix of longer periods of market exclusivity, tax credits, streamlined regulatory routes, and high-priced structures that have drawn substantial investment from the entire pharmaceutical sector.
Download Report: https://www.kuickresearch.com/report-fda-orphan-drug-database
Major pharmaceutical companies have initiated a strategic incursion into the US orphan disease space with a focus on small patient groups for large return on revenues. Pfizer's Vyndaqel (tafamidis) is a classic case, growing into a blockbusting by 2020. Since 2021, it has crossed over US$ 2 billion a year, hitting over US$ 5 billion in 2024 while treating about 100,000 patients in the US. In a similar vein, Vertex Pharmaceuticals constructed its multibillion-dollar business largely through its pioneering cystic fibrosis therapies, such as Trikafta, which supports premium prices while significantly enhancing outcomes for the approximately 30,000 eligible patients in the US.
The landscape of orphan drugs has also supported the emergence of specialized biotech firms that are focused entirely on rare disease medicines. Alexion Pharmaceuticals, which was purchased by AstraZeneca for US$ 39 billion in 2021, led the way with Soliris (eculizumab) in the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Even though it targeted highly niche patient populations, Soliris became a blockbuster in its premium pricing model. BioMarin Pharmaceutical has also built a profitable business on rare disease drugs like Vimizim for Morquio A syndrome, which impacts fewer than 3,000 Americans but is highly economic.
The financials of orphan drugs have created new models of drug development and commercialization. Novartis's Zolgensma for spinal muscular atrophy, which was priced at one-time US$ 2.1 million, is a breakthrough in therapeutic value and pricing models. Companies have introduced new payment schemes, such as outcomes-based arrangements where compensation is based on patients meeting certain clinical milestones. These models align economic incentives with therapeutic value while making treatments accessible to patients.
The orphan drug market continues to be helped by leading-edge scientific developments, most notably in gene and cell therapies. Bluebird bio's Zynteglo for beta-thalassemia is a prime example of this trend, providing potentially curative therapy for a previously chronically treated disease. At the same time, biotech companies such as Sarepta Therapeutics have led the way with RNA-targeted therapies such as Exondys 51 for Duchenne muscular dystrophy, creating new therapeutic paradigms for genetic diseases with small patient populations.
The orphan drug market has also grown outside the US, as domestic companies discovered new opportunities in foreign markets developing their own orphan drug systems. Ultragenyx Pharmaceutical successfully launched Crysvita for X-linked hypophosphatemia in several worldwide regions, while Horizon Therapeutics (now under Amgen) has built out Tepezza for thyroid eye disease as a worldwide rare disease franchise. These worldwide expansions have provided other sources of revenue for US developers while making novel treatments available to global patients.
As technological innovation and scientific knowledge of rare diseases expand, the US orphan drug market is set for ongoing growth and innovation. In spite of challenges such as high expense, it is one of the most dynamic and lucrative healthcare sectors. This is a testament to a formidable intersection of scientific advancement, patient activism, regulatory support, and strategic investment, all of which are reshaping treatment options for millions of American patients with rare diseases. US Orphan Drug Market US Orphan Drug Market size US Orphan Drug Market forecast US Orphan Drug Market growth US Orphan Drug Market future US Orphan Drug Market billion US Orphan Drug Market sales US rare disease Market US rare disease Market size fda approved orphan drugs